Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014‐04 (Etoile du Nord) trial Article Swipe
Eileen M. Boyle
,
Xavier Leleu
,
Marie-Odile Pétillon
,
Lionel Karlin
,
Chantal Doyen
,
Hélène Demarquette
,
Bruno Royer
,
Margaret Macro
,
Philippe Moreau
,
Karel Fostier
,
Chretien Marie‐Lorraine
,
Charles Zarnitsky
,
Aurore Perrot
,
Charles Herbaux
,
Stéphanie Poulain
,
Salomon Manier
,
David Beauvais
,
Brian A. Walker
,
Christopher P. Wardell
,
Laure Vincent
,
Laurent Frenzel
,
Hélène Caillon
,
Susanna Schraen
,
Thomas Dejoie
,
Hervé Avet‐Loiseau
,
Mohamad Mohty
,
Thierry Façon
·
YOU?
·
· 2019
· Open Access
·
· DOI: https://doi.org/10.1111/bjh.16059
YOU?
·
· 2019
· Open Access
·
· DOI: https://doi.org/10.1111/bjh.16059
Summary Single agent daratumumab has shown clinical activity in relapsed, refractory multiple myeloma (RRMM). The Intergroupe Francophone du Myélome 2014‐04 trial was designed to further investigate daratumumab in combination with dexamethasone in triple RRMM patients. Patients received daratumumab infusions in combination with weekly dexamethasone until disease progression or unacceptable toxicity. Fifty‐seven patients were included in the trial and evaluable for response. The overall response rate and the clinical benefit rate were 33% ( n = 19) and 48% ( n = 27), respectively. Five (8·8%) patients achieved a very good partial response or better. The median time to response was 4 weeks. For responding patients, the median progression‐free survival was 6·6 months, compared to 3·7 months (3·0–5·5) for those with a minimal or stable disease. The median overall survival (OS) for all patients was 16·7 months (11·2–24·0). For responding patients, the median OS was 23·23 months, whereas that of patients with progressive disease was 2·97 months. The incidence of infusion‐related reactions was 37%; all cases were manageable and did not lead to dose reduction or permanent treatment discontinuation. These data demonstrate that treatment with daratumumab and dexamethasone results in a meaningful long‐term benefit with an acceptable safety profile for patients with triple RRMM.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1111/bjh.16059
- https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bjh.16059
- OA Status
- bronze
- Cited By
- 22
- References
- 24
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W2949444027
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W2949444027Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1111/bjh.16059Digital Object Identifier
- Title
-
Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014‐04 (Etoile du Nord) trialWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2019Year of publication
- Publication date
-
2019-06-19Full publication date if available
- Authors
-
Eileen M. Boyle, Xavier Leleu, Marie-Odile Pétillon, Lionel Karlin, Chantal Doyen, Hélène Demarquette, Bruno Royer, Margaret Macro, Philippe Moreau, Karel Fostier, Chretien Marie‐Lorraine, Charles Zarnitsky, Aurore Perrot, Charles Herbaux, Stéphanie Poulain, Salomon Manier, David Beauvais, Brian A. Walker, Christopher P. Wardell, Laure Vincent, Laurent Frenzel, Hélène Caillon, Susanna Schraen, Thomas Dejoie, Hervé Avet‐Loiseau, Mohamad Mohty, Thierry FaçonList of authors in order
- Landing page
-
https://doi.org/10.1111/bjh.16059Publisher landing page
- PDF URL
-
https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bjh.16059Direct link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
bronzeOpen access status per OpenAlex
- OA URL
-
https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bjh.16059Direct OA link when available
- Concepts
-
Medicine, Daratumumab, Dexamethasone, Discontinuation, Internal medicine, Multiple myeloma, Refractory (planetary science), Surgery, Clinical trial, Oncology, Lenalidomide, Physics, AstrobiologyTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
22Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 1, 2024: 2, 2023: 5, 2022: 3, 2021: 5Per-year citation counts (last 5 years)
- References (count)
-
24Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W2949444027 |
|---|---|
| doi | https://doi.org/10.1111/bjh.16059 |
| ids.doi | https://doi.org/10.1111/bjh.16059 |
| ids.mag | 2949444027 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/31218679 |
| ids.openalex | https://openalex.org/W2949444027 |
| fwci | 2.92083539 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D000328 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Adult |
| mesh[1].qualifier_ui | |
| mesh[1].descriptor_ui | D000368 |
| mesh[1].is_major_topic | False |
| mesh[1].qualifier_name | |
| mesh[1].descriptor_name | Aged |
| mesh[2].qualifier_ui | |
| mesh[2].descriptor_ui | D000369 |
| mesh[2].is_major_topic | False |
| mesh[2].qualifier_name | |
| mesh[2].descriptor_name | Aged, 80 and over |
| mesh[3].qualifier_ui | Q000008 |
| mesh[3].descriptor_ui | D000911 |
| mesh[3].is_major_topic | False |
| mesh[3].qualifier_name | administration & dosage |
| mesh[3].descriptor_name | Antibodies, Monoclonal |
| mesh[4].qualifier_ui | Q000009 |
| mesh[4].descriptor_ui | D000911 |
| mesh[4].is_major_topic | False |
| mesh[4].qualifier_name | adverse effects |
| mesh[4].descriptor_name | Antibodies, Monoclonal |
| mesh[5].qualifier_ui | Q000008 |
| mesh[5].descriptor_ui | D000971 |
| mesh[5].is_major_topic | False |
| mesh[5].qualifier_name | administration & dosage |
| mesh[5].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[6].qualifier_ui | Q000009 |
| mesh[6].descriptor_ui | D000971 |
| mesh[6].is_major_topic | False |
| mesh[6].qualifier_name | adverse effects |
| mesh[6].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[7].qualifier_ui | Q000008 |
| mesh[7].descriptor_ui | D003907 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | administration & dosage |
| mesh[7].descriptor_name | Dexamethasone |
| mesh[8].qualifier_ui | Q000009 |
| mesh[8].descriptor_ui | D003907 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | adverse effects |
| mesh[8].descriptor_name | Dexamethasone |
| mesh[9].qualifier_ui | |
| mesh[9].descriptor_ui | D018572 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | |
| mesh[9].descriptor_name | Disease-Free Survival |
| mesh[10].qualifier_ui | |
| mesh[10].descriptor_ui | D005260 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | |
| mesh[10].descriptor_name | Female |
| mesh[11].qualifier_ui | |
| mesh[11].descriptor_ui | D006801 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | |
| mesh[11].descriptor_name | Humans |
| mesh[12].qualifier_ui | |
| mesh[12].descriptor_ui | D008297 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | |
| mesh[12].descriptor_name | Male |
| mesh[13].qualifier_ui | |
| mesh[13].descriptor_ui | D008875 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | |
| mesh[13].descriptor_name | Middle Aged |
| mesh[14].qualifier_ui | Q000188 |
| mesh[14].descriptor_ui | D009101 |
| mesh[14].is_major_topic | False |
| mesh[14].qualifier_name | drug therapy |
| mesh[14].descriptor_name | Multiple Myeloma |
| mesh[15].qualifier_ui | Q000401 |
| mesh[15].descriptor_ui | D009101 |
| mesh[15].is_major_topic | False |
| mesh[15].qualifier_name | mortality |
| mesh[15].descriptor_name | Multiple Myeloma |
| mesh[16].qualifier_ui | |
| mesh[16].descriptor_ui | D015996 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | |
| mesh[16].descriptor_name | Survival Rate |
| mesh[17].qualifier_ui | |
| mesh[17].descriptor_ui | D000328 |
| mesh[17].is_major_topic | False |
| mesh[17].qualifier_name | |
| mesh[17].descriptor_name | Adult |
| mesh[18].qualifier_ui | |
| mesh[18].descriptor_ui | D000368 |
| mesh[18].is_major_topic | False |
| mesh[18].qualifier_name | |
| mesh[18].descriptor_name | Aged |
| mesh[19].qualifier_ui | |
| mesh[19].descriptor_ui | D000369 |
| mesh[19].is_major_topic | False |
| mesh[19].qualifier_name | |
| mesh[19].descriptor_name | Aged, 80 and over |
| mesh[20].qualifier_ui | Q000008 |
| mesh[20].descriptor_ui | D000911 |
| mesh[20].is_major_topic | False |
| mesh[20].qualifier_name | administration & dosage |
| mesh[20].descriptor_name | Antibodies, Monoclonal |
| mesh[21].qualifier_ui | Q000009 |
| mesh[21].descriptor_ui | D000911 |
| mesh[21].is_major_topic | False |
| mesh[21].qualifier_name | adverse effects |
| mesh[21].descriptor_name | Antibodies, Monoclonal |
| mesh[22].qualifier_ui | Q000008 |
| mesh[22].descriptor_ui | D000971 |
| mesh[22].is_major_topic | False |
| mesh[22].qualifier_name | administration & dosage |
| mesh[22].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[23].qualifier_ui | Q000009 |
| mesh[23].descriptor_ui | D000971 |
| mesh[23].is_major_topic | False |
| mesh[23].qualifier_name | adverse effects |
| mesh[23].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[24].qualifier_ui | Q000008 |
| mesh[24].descriptor_ui | D003907 |
| mesh[24].is_major_topic | False |
| mesh[24].qualifier_name | administration & dosage |
| mesh[24].descriptor_name | Dexamethasone |
| mesh[25].qualifier_ui | Q000009 |
| mesh[25].descriptor_ui | D003907 |
| mesh[25].is_major_topic | False |
| mesh[25].qualifier_name | adverse effects |
| mesh[25].descriptor_name | Dexamethasone |
| mesh[26].qualifier_ui | |
| mesh[26].descriptor_ui | D018572 |
| mesh[26].is_major_topic | False |
| mesh[26].qualifier_name | |
| mesh[26].descriptor_name | Disease-Free Survival |
| mesh[27].qualifier_ui | |
| mesh[27].descriptor_ui | D005260 |
| mesh[27].is_major_topic | False |
| mesh[27].qualifier_name | |
| mesh[27].descriptor_name | Female |
| mesh[28].qualifier_ui | |
| mesh[28].descriptor_ui | D006801 |
| mesh[28].is_major_topic | False |
| mesh[28].qualifier_name | |
| mesh[28].descriptor_name | Humans |
| mesh[29].qualifier_ui | |
| mesh[29].descriptor_ui | D008297 |
| mesh[29].is_major_topic | False |
| mesh[29].qualifier_name | |
| mesh[29].descriptor_name | Male |
| mesh[30].qualifier_ui | |
| mesh[30].descriptor_ui | D008875 |
| mesh[30].is_major_topic | False |
| mesh[30].qualifier_name | |
| mesh[30].descriptor_name | Middle Aged |
| mesh[31].qualifier_ui | Q000188 |
| mesh[31].descriptor_ui | D009101 |
| mesh[31].is_major_topic | False |
| mesh[31].qualifier_name | drug therapy |
| mesh[31].descriptor_name | Multiple Myeloma |
| mesh[32].qualifier_ui | Q000401 |
| mesh[32].descriptor_ui | D009101 |
| mesh[32].is_major_topic | False |
| mesh[32].qualifier_name | mortality |
| mesh[32].descriptor_name | Multiple Myeloma |
| mesh[33].qualifier_ui | |
| mesh[33].descriptor_ui | D015996 |
| mesh[33].is_major_topic | False |
| mesh[33].qualifier_name | |
| mesh[33].descriptor_name | Survival Rate |
| type | article |
| title | Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014‐04 (Etoile du Nord) trial |
| biblio.issue | 3 |
| biblio.volume | 187 |
| biblio.last_page | 327 |
| biblio.first_page | 319 |
| topics[0].id | https://openalex.org/T10649 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 1.0 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2720 |
| topics[0].subfield.display_name | Hematology |
| topics[0].display_name | Multiple Myeloma Research and Treatments |
| topics[1].id | https://openalex.org/T12505 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9937000274658203 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2730 |
| topics[1].subfield.display_name | Oncology |
| topics[1].display_name | Peptidase Inhibition and Analysis |
| topics[2].id | https://openalex.org/T11752 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9898999929428101 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2730 |
| topics[2].subfield.display_name | Oncology |
| topics[2].display_name | Cancer Treatment and Pharmacology |
| is_xpac | False |
| apc_list.value | 4940 |
| apc_list.currency | USD |
| apc_list.value_usd | 4940 |
| apc_paid | |
| concepts[0].id | https://openalex.org/C71924100 |
| concepts[0].level | 0 |
| concepts[0].score | 0.9206374883651733 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[0].display_name | Medicine |
| concepts[1].id | https://openalex.org/C2781119759 |
| concepts[1].level | 4 |
| concepts[1].score | 0.9101289510726929 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q5222113 |
| concepts[1].display_name | Daratumumab |
| concepts[2].id | https://openalex.org/C2780401358 |
| concepts[2].level | 2 |
| concepts[2].score | 0.7609318494796753 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q422252 |
| concepts[2].display_name | Dexamethasone |
| concepts[3].id | https://openalex.org/C2778715236 |
| concepts[3].level | 2 |
| concepts[3].score | 0.6446335315704346 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q55622662 |
| concepts[3].display_name | Discontinuation |
| concepts[4].id | https://openalex.org/C126322002 |
| concepts[4].level | 1 |
| concepts[4].score | 0.5867571234703064 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[4].display_name | Internal medicine |
| concepts[5].id | https://openalex.org/C2776364478 |
| concepts[5].level | 2 |
| concepts[5].score | 0.5204265713691711 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q467635 |
| concepts[5].display_name | Multiple myeloma |
| concepts[6].id | https://openalex.org/C142424586 |
| concepts[6].level | 2 |
| concepts[6].score | 0.5126703977584839 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q7307572 |
| concepts[6].display_name | Refractory (planetary science) |
| concepts[7].id | https://openalex.org/C141071460 |
| concepts[7].level | 1 |
| concepts[7].score | 0.4562867283821106 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q40821 |
| concepts[7].display_name | Surgery |
| concepts[8].id | https://openalex.org/C535046627 |
| concepts[8].level | 2 |
| concepts[8].score | 0.4285687506198883 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q30612 |
| concepts[8].display_name | Clinical trial |
| concepts[9].id | https://openalex.org/C143998085 |
| concepts[9].level | 1 |
| concepts[9].score | 0.3455716371536255 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[9].display_name | Oncology |
| concepts[10].id | https://openalex.org/C2776063141 |
| concepts[10].level | 3 |
| concepts[10].score | 0.22250869870185852 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q425681 |
| concepts[10].display_name | Lenalidomide |
| concepts[11].id | https://openalex.org/C121332964 |
| concepts[11].level | 0 |
| concepts[11].score | 0.0 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q413 |
| concepts[11].display_name | Physics |
| concepts[12].id | https://openalex.org/C87355193 |
| concepts[12].level | 1 |
| concepts[12].score | 0.0 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q411 |
| concepts[12].display_name | Astrobiology |
| keywords[0].id | https://openalex.org/keywords/medicine |
| keywords[0].score | 0.9206374883651733 |
| keywords[0].display_name | Medicine |
| keywords[1].id | https://openalex.org/keywords/daratumumab |
| keywords[1].score | 0.9101289510726929 |
| keywords[1].display_name | Daratumumab |
| keywords[2].id | https://openalex.org/keywords/dexamethasone |
| keywords[2].score | 0.7609318494796753 |
| keywords[2].display_name | Dexamethasone |
| keywords[3].id | https://openalex.org/keywords/discontinuation |
| keywords[3].score | 0.6446335315704346 |
| keywords[3].display_name | Discontinuation |
| keywords[4].id | https://openalex.org/keywords/internal-medicine |
| keywords[4].score | 0.5867571234703064 |
| keywords[4].display_name | Internal medicine |
| keywords[5].id | https://openalex.org/keywords/multiple-myeloma |
| keywords[5].score | 0.5204265713691711 |
| keywords[5].display_name | Multiple myeloma |
| keywords[6].id | https://openalex.org/keywords/refractory |
| keywords[6].score | 0.5126703977584839 |
| keywords[6].display_name | Refractory (planetary science) |
| keywords[7].id | https://openalex.org/keywords/surgery |
| keywords[7].score | 0.4562867283821106 |
| keywords[7].display_name | Surgery |
| keywords[8].id | https://openalex.org/keywords/clinical-trial |
| keywords[8].score | 0.4285687506198883 |
| keywords[8].display_name | Clinical trial |
| keywords[9].id | https://openalex.org/keywords/oncology |
| keywords[9].score | 0.3455716371536255 |
| keywords[9].display_name | Oncology |
| keywords[10].id | https://openalex.org/keywords/lenalidomide |
| keywords[10].score | 0.22250869870185852 |
| keywords[10].display_name | Lenalidomide |
| language | en |
| locations[0].id | doi:10.1111/bjh.16059 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S153015021 |
| locations[0].source.issn | 0007-1048, 1365-2141 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 0007-1048 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | British Journal of Haematology |
| locations[0].source.host_organization | https://openalex.org/P4310320595 |
| locations[0].source.host_organization_name | Wiley |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320595 |
| locations[0].license | |
| locations[0].pdf_url | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bjh.16059 |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | British Journal of Haematology |
| locations[0].landing_page_url | https://doi.org/10.1111/bjh.16059 |
| locations[1].id | pmh:oai:vubissmart:VUBISSMART:2000:171947 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306402573 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | VUBIR (Vrije Universiteit Brussel) |
| locations[1].source.host_organization | https://openalex.org/I13469542 |
| locations[1].source.host_organization_name | Vrije Universiteit Brussel |
| locations[1].source.host_organization_lineage | https://openalex.org/I13469542 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | publishedVersion |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | |
| locations[1].landing_page_url | https://biblio.vub.ac.be/vubir/(187eead9-5b0f-4e96-916a-002fe72d9e9a).html |
| locations[2].id | pmid:31218679 |
| locations[2].is_oa | False |
| locations[2].source.id | https://openalex.org/S4306525036 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | PubMed |
| locations[2].source.host_organization | https://openalex.org/I1299303238 |
| locations[2].source.host_organization_name | National Institutes of Health |
| locations[2].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[2].license | |
| locations[2].pdf_url | |
| locations[2].version | publishedVersion |
| locations[2].raw_type | |
| locations[2].license_id | |
| locations[2].is_accepted | True |
| locations[2].is_published | True |
| locations[2].raw_source_name | British journal of haematology |
| locations[2].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/31218679 |
| locations[3].id | pmh:oai:dial.uclouvain.be:boreal:217503 |
| locations[3].is_oa | True |
| locations[3].source.id | https://openalex.org/S4306400166 |
| locations[3].source.issn | |
| locations[3].source.type | repository |
| locations[3].source.is_oa | False |
| locations[3].source.issn_l | |
| locations[3].source.is_core | False |
| locations[3].source.is_in_doaj | False |
| locations[3].source.display_name | Digital Access to Libraries |
| locations[3].source.host_organization | https://openalex.org/I2800384882 |
| locations[3].source.host_organization_name | Harris County Public Library |
| locations[3].source.host_organization_lineage | https://openalex.org/I2800384882 |
| locations[3].license | other-oa |
| locations[3].pdf_url | |
| locations[3].version | submittedVersion |
| locations[3].raw_type | info:eu-repo/semantics/article |
| locations[3].license_id | https://openalex.org/licenses/other-oa |
| locations[3].is_accepted | False |
| locations[3].is_published | False |
| locations[3].raw_source_name | British journal of haematology, Vol. 187, no. 3, p. 319-327 (2019) |
| locations[3].landing_page_url | http://hdl.handle.net/2078.1/217503 |
| locations[4].id | pmh:oai:vubissmart:VUBISSMART:2000:208955 |
| locations[4].is_oa | False |
| locations[4].source.id | https://openalex.org/S4306402573 |
| locations[4].source.issn | |
| locations[4].source.type | repository |
| locations[4].source.is_oa | False |
| locations[4].source.issn_l | |
| locations[4].source.is_core | False |
| locations[4].source.is_in_doaj | False |
| locations[4].source.display_name | VUBIR (Vrije Universiteit Brussel) |
| locations[4].source.host_organization | https://openalex.org/I13469542 |
| locations[4].source.host_organization_name | Vrije Universiteit Brussel |
| locations[4].source.host_organization_lineage | https://openalex.org/I13469542 |
| locations[4].license | |
| locations[4].pdf_url | |
| locations[4].version | submittedVersion |
| locations[4].raw_type | article |
| locations[4].license_id | |
| locations[4].is_accepted | False |
| locations[4].is_published | False |
| locations[4].raw_source_name | |
| locations[4].landing_page_url | |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5013925872 |
| authorships[0].author.orcid | https://orcid.org/0000-0001-8791-1744 |
| authorships[0].author.display_name | Eileen M. Boyle |
| authorships[0].countries | FR |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210155195 |
| authorships[0].affiliations[0].raw_affiliation_string | Department of Haematology Hôpital Claude Huriez, Lille University Hospital Lille France |
| authorships[0].institutions[0].id | https://openalex.org/I4210155195 |
| authorships[0].institutions[0].ror | https://ror.org/05cpv3t46 |
| authorships[0].institutions[0].type | healthcare |
| authorships[0].institutions[0].lineage | https://openalex.org/I3018718406, https://openalex.org/I4210155195 |
| authorships[0].institutions[0].country_code | FR |
| authorships[0].institutions[0].display_name | Hôpital Claude Huriez |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Eileen M. Boyle |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Department of Haematology Hôpital Claude Huriez, Lille University Hospital Lille France |
| authorships[1].author.id | https://openalex.org/A5048560248 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-9822-4170 |
| authorships[1].author.display_name | Xavier Leleu |
| authorships[1].affiliations[0].raw_affiliation_string | Department of Haematology Hôpital de la Miletrie, Poitiers University Hospital Poitiers France |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Xavier Leleu |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Department of Haematology Hôpital de la Miletrie, Poitiers University Hospital Poitiers France |
| authorships[2].author.id | https://openalex.org/A5005909959 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Marie-Odile Pétillon |
| authorships[2].countries | FR |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210155195 |
| authorships[2].affiliations[0].raw_affiliation_string | Department of Haematology Hôpital Claude Huriez, Lille University Hospital Lille France |
| authorships[2].institutions[0].id | https://openalex.org/I4210155195 |
| authorships[2].institutions[0].ror | https://ror.org/05cpv3t46 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I3018718406, https://openalex.org/I4210155195 |
| authorships[2].institutions[0].country_code | FR |
| authorships[2].institutions[0].display_name | Hôpital Claude Huriez |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Marie‐Odile Petillon |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Department of Haematology Hôpital Claude Huriez, Lille University Hospital Lille France |
| authorships[3].author.id | https://openalex.org/A5044238802 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Lionel Karlin |
| authorships[3].countries | FR |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I4210100596, https://openalex.org/I4210113288 |
| authorships[3].affiliations[0].raw_affiliation_string | Department of Haematology Hôpital Lyon Sud, Lyon University Hospital Pierre‐Bénite France |
| authorships[3].institutions[0].id | https://openalex.org/I4210100596 |
| authorships[3].institutions[0].ror | https://ror.org/01502ca60 |
| authorships[3].institutions[0].type | healthcare |
| authorships[3].institutions[0].lineage | https://openalex.org/I4210100596 |
| authorships[3].institutions[0].country_code | FR |
| authorships[3].institutions[0].display_name | Hospices Civils de Lyon |
| authorships[3].institutions[1].id | https://openalex.org/I4210113288 |
| authorships[3].institutions[1].ror | https://ror.org/023xgd207 |
| authorships[3].institutions[1].type | healthcare |
| authorships[3].institutions[1].lineage | https://openalex.org/I4210100596, https://openalex.org/I4210113288 |
| authorships[3].institutions[1].country_code | FR |
| authorships[3].institutions[1].display_name | Hôpital Lyon Sud |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Lionel Karlin |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Department of Haematology Hôpital Lyon Sud, Lyon University Hospital Pierre‐Bénite France |
| authorships[4].author.id | https://openalex.org/A5087052731 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-8272-9158 |
| authorships[4].author.display_name | Chantal Doyen |
| authorships[4].countries | BE |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I4210093617 |
| authorships[4].affiliations[0].raw_affiliation_string | Department of Haematology, CHU Dinant Godinne, UCL Namur, Yvoir, Belgium |
| authorships[4].institutions[0].id | https://openalex.org/I4210093617 |
| authorships[4].institutions[0].ror | https://ror.org/00ntbvq76 |
| authorships[4].institutions[0].type | healthcare |
| authorships[4].institutions[0].lineage | https://openalex.org/I4210093617 |
| authorships[4].institutions[0].country_code | BE |
| authorships[4].institutions[0].display_name | CHU Dinant Godinne UCL Namur |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Chantal Doyen |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Department of Haematology, CHU Dinant Godinne, UCL Namur, Yvoir, Belgium |
| authorships[5].author.id | https://openalex.org/A5015559721 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | Hélène Demarquette |
| authorships[5].countries | FR |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I4210155148 |
| authorships[5].affiliations[0].raw_affiliation_string | Department of Haematology Hospitalier Général Dunkerque France |
| authorships[5].institutions[0].id | https://openalex.org/I4210155148 |
| authorships[5].institutions[0].ror | https://ror.org/05evp6y14 |
| authorships[5].institutions[0].type | healthcare |
| authorships[5].institutions[0].lineage | https://openalex.org/I4210155148 |
| authorships[5].institutions[0].country_code | FR |
| authorships[5].institutions[0].display_name | Générale de Santé |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Hélène Demarquette |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Department of Haematology Hospitalier Général Dunkerque France |
| authorships[6].author.id | https://openalex.org/A5077081397 |
| authorships[6].author.orcid | https://orcid.org/0000-0002-8649-7008 |
| authorships[6].author.display_name | Bruno Royer |
| authorships[6].countries | FR |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I4210144610 |
| authorships[6].affiliations[0].raw_affiliation_string | Department of Haematology Hôpital St Louis Paris France |
| authorships[6].institutions[0].id | https://openalex.org/I4210144610 |
| authorships[6].institutions[0].ror | https://ror.org/049am9t04 |
| authorships[6].institutions[0].type | healthcare |
| authorships[6].institutions[0].lineage | https://openalex.org/I4210097159, https://openalex.org/I4210144610 |
| authorships[6].institutions[0].country_code | FR |
| authorships[6].institutions[0].display_name | Hôpital Saint-Louis |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Bruno Royer |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Department of Haematology Hôpital St Louis Paris France |
| authorships[7].author.id | https://openalex.org/A5069745915 |
| authorships[7].author.orcid | https://orcid.org/0000-0002-0460-0658 |
| authorships[7].author.display_name | Margaret Macro |
| authorships[7].countries | FR |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I98702875 |
| authorships[7].affiliations[0].raw_affiliation_string | Department of Haematology, CHRU Cote de Nacre, Caen University Hospital, Caen, France |
| authorships[7].institutions[0].id | https://openalex.org/I98702875 |
| authorships[7].institutions[0].ror | https://ror.org/051kpcy16 |
| authorships[7].institutions[0].type | education |
| authorships[7].institutions[0].lineage | https://openalex.org/I4210105918, https://openalex.org/I98702875 |
| authorships[7].institutions[0].country_code | FR |
| authorships[7].institutions[0].display_name | Université de Caen Normandie |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Margaret Macro |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Department of Haematology, CHRU Cote de Nacre, Caen University Hospital, Caen, France |
| authorships[8].author.id | https://openalex.org/A5103143602 |
| authorships[8].author.orcid | https://orcid.org/0000-0003-1780-8746 |
| authorships[8].author.display_name | Philippe Moreau |
| authorships[8].affiliations[0].raw_affiliation_string | Department of Haematology CHRU Hôtel Dieu, Nantes, University Hospital Nantes France |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Philippe Moreau |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Department of Haematology CHRU Hôtel Dieu, Nantes, University Hospital Nantes France |
| authorships[9].author.id | https://openalex.org/A5046139100 |
| authorships[9].author.orcid | |
| authorships[9].author.display_name | Karel Fostier |
| authorships[9].countries | BE |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I4210126764 |
| authorships[9].affiliations[0].raw_affiliation_string | Department of Haematology, UZ Brussel, Brussels, Belgium |
| authorships[9].institutions[0].id | https://openalex.org/I4210126764 |
| authorships[9].institutions[0].ror | https://ror.org/038f7y939 |
| authorships[9].institutions[0].type | healthcare |
| authorships[9].institutions[0].lineage | https://openalex.org/I4210126764 |
| authorships[9].institutions[0].country_code | BE |
| authorships[9].institutions[0].display_name | Universitair Ziekenhuis Brussel |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Karel Fostier |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Department of Haematology, UZ Brussel, Brussels, Belgium |
| authorships[10].author.id | https://openalex.org/A5098027730 |
| authorships[10].author.orcid | |
| authorships[10].author.display_name | Chretien Marie‐Lorraine |
| authorships[10].countries | FR |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I4210142595 |
| authorships[10].affiliations[0].raw_affiliation_string | Department of Haematology, University Hospital, Dijon, France |
| authorships[10].institutions[0].id | https://openalex.org/I4210142595 |
| authorships[10].institutions[0].ror | https://ror.org/04ejcwb57 |
| authorships[10].institutions[0].type | facility |
| authorships[10].institutions[0].lineage | https://openalex.org/I1294671590, https://openalex.org/I4210142595, https://openalex.org/I4210150854, https://openalex.org/I4407990431 |
| authorships[10].institutions[0].country_code | FR |
| authorships[10].institutions[0].display_name | Maison des Sciences sociales et des Humanités de Dijon |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Chretien Marie‐Lorraine |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | Department of Haematology, University Hospital, Dijon, France |
| authorships[11].author.id | https://openalex.org/A5111984409 |
| authorships[11].author.orcid | |
| authorships[11].author.display_name | Charles Zarnitsky |
| authorships[11].countries | FR |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I4210124040 |
| authorships[11].affiliations[0].raw_affiliation_string | Department of Haematology, Centre Hospitalier J. Monod, CH du Havre, Le Havre, France |
| authorships[11].institutions[0].id | https://openalex.org/I4210124040 |
| authorships[11].institutions[0].ror | https://ror.org/02pve7657 |
| authorships[11].institutions[0].type | healthcare |
| authorships[11].institutions[0].lineage | https://openalex.org/I4210124040 |
| authorships[11].institutions[0].country_code | FR |
| authorships[11].institutions[0].display_name | Groupe Hospitalier du Havre |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Charles Zarnitsky |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | Department of Haematology, Centre Hospitalier J. Monod, CH du Havre, Le Havre, France |
| authorships[12].author.id | https://openalex.org/A5082698003 |
| authorships[12].author.orcid | https://orcid.org/0000-0003-0131-8689 |
| authorships[12].author.display_name | Aurore Perrot |
| authorships[12].countries | FR |
| authorships[12].affiliations[0].institution_ids | https://openalex.org/I4210100260 |
| authorships[12].affiliations[0].raw_affiliation_string | Department of Haematology Hôpitaux de Brabois, CHRU Nancy Nancy France |
| authorships[12].institutions[0].id | https://openalex.org/I4210100260 |
| authorships[12].institutions[0].ror | https://ror.org/016ncsr12 |
| authorships[12].institutions[0].type | healthcare |
| authorships[12].institutions[0].lineage | https://openalex.org/I4210100260 |
| authorships[12].institutions[0].country_code | FR |
| authorships[12].institutions[0].display_name | Centre Hospitalier Régional et Universitaire de Nancy |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | Aurore Perrot |
| authorships[12].is_corresponding | False |
| authorships[12].raw_affiliation_strings | Department of Haematology Hôpitaux de Brabois, CHRU Nancy Nancy France |
| authorships[13].author.id | https://openalex.org/A5045486705 |
| authorships[13].author.orcid | https://orcid.org/0000-0003-4910-476X |
| authorships[13].author.display_name | Charles Herbaux |
| authorships[13].countries | FR |
| authorships[13].affiliations[0].institution_ids | https://openalex.org/I4210155195 |
| authorships[13].affiliations[0].raw_affiliation_string | Department of Haematology Hôpital Claude Huriez, Lille University Hospital Lille France |
| authorships[13].institutions[0].id | https://openalex.org/I4210155195 |
| authorships[13].institutions[0].ror | https://ror.org/05cpv3t46 |
| authorships[13].institutions[0].type | healthcare |
| authorships[13].institutions[0].lineage | https://openalex.org/I3018718406, https://openalex.org/I4210155195 |
| authorships[13].institutions[0].country_code | FR |
| authorships[13].institutions[0].display_name | Hôpital Claude Huriez |
| authorships[13].author_position | middle |
| authorships[13].raw_author_name | Charles Herbaux |
| authorships[13].is_corresponding | False |
| authorships[13].raw_affiliation_strings | Department of Haematology Hôpital Claude Huriez, Lille University Hospital Lille France |
| authorships[14].author.id | https://openalex.org/A5012731491 |
| authorships[14].author.orcid | https://orcid.org/0000-0002-1792-7270 |
| authorships[14].author.display_name | Stéphanie Poulain |
| authorships[14].countries | FR |
| authorships[14].affiliations[0].institution_ids | https://openalex.org/I4210163910 |
| authorships[14].affiliations[0].raw_affiliation_string | Service d’Hématologie Cellulaire, Centre de Biologie Pathologie Lille University Hospital Lille France |
| authorships[14].affiliations[1].institution_ids | https://openalex.org/I154526488, https://openalex.org/I2279609970 |
| authorships[14].affiliations[1].raw_affiliation_string | INSERM UMRS 1172 Lille France |
| authorships[14].institutions[0].id | https://openalex.org/I154526488 |
| authorships[14].institutions[0].ror | https://ror.org/02vjkv261 |
| authorships[14].institutions[0].type | government |
| authorships[14].institutions[0].lineage | https://openalex.org/I154526488 |
| authorships[14].institutions[0].country_code | FR |
| authorships[14].institutions[0].display_name | Inserm |
| authorships[14].institutions[1].id | https://openalex.org/I4210163910 |
| authorships[14].institutions[1].ror | https://ror.org/05gd4yq49 |
| authorships[14].institutions[1].type | facility |
| authorships[14].institutions[1].lineage | https://openalex.org/I154526488, https://openalex.org/I2279609970, https://openalex.org/I2800921988, https://openalex.org/I4210163910 |
| authorships[14].institutions[1].country_code | FR |
| authorships[14].institutions[1].display_name | Institut de Biologie de Lille |
| authorships[14].institutions[2].id | https://openalex.org/I2279609970 |
| authorships[14].institutions[2].ror | https://ror.org/02kzqn938 |
| authorships[14].institutions[2].type | education |
| authorships[14].institutions[2].lineage | https://openalex.org/I2279609970 |
| authorships[14].institutions[2].country_code | FR |
| authorships[14].institutions[2].display_name | Université de Lille |
| authorships[14].author_position | middle |
| authorships[14].raw_author_name | Stephanie Poulain |
| authorships[14].is_corresponding | False |
| authorships[14].raw_affiliation_strings | INSERM UMRS 1172 Lille France, Service d’Hématologie Cellulaire, Centre de Biologie Pathologie Lille University Hospital Lille France |
| authorships[15].author.id | https://openalex.org/A5036677725 |
| authorships[15].author.orcid | https://orcid.org/0000-0001-7653-711X |
| authorships[15].author.display_name | Salomon Manier |
| authorships[15].countries | FR |
| authorships[15].affiliations[0].institution_ids | https://openalex.org/I4210155195 |
| authorships[15].affiliations[0].raw_affiliation_string | Department of Haematology Hôpital Claude Huriez, Lille University Hospital Lille France |
| authorships[15].institutions[0].id | https://openalex.org/I4210155195 |
| authorships[15].institutions[0].ror | https://ror.org/05cpv3t46 |
| authorships[15].institutions[0].type | healthcare |
| authorships[15].institutions[0].lineage | https://openalex.org/I3018718406, https://openalex.org/I4210155195 |
| authorships[15].institutions[0].country_code | FR |
| authorships[15].institutions[0].display_name | Hôpital Claude Huriez |
| authorships[15].author_position | middle |
| authorships[15].raw_author_name | Salomon Manier |
| authorships[15].is_corresponding | False |
| authorships[15].raw_affiliation_strings | Department of Haematology Hôpital Claude Huriez, Lille University Hospital Lille France |
| authorships[16].author.id | https://openalex.org/A5039031509 |
| authorships[16].author.orcid | https://orcid.org/0000-0003-1866-828X |
| authorships[16].author.display_name | David Beauvais |
| authorships[16].countries | FR |
| authorships[16].affiliations[0].institution_ids | https://openalex.org/I4210155195 |
| authorships[16].affiliations[0].raw_affiliation_string | Department of Haematology Hôpital Claude Huriez, Lille University Hospital Lille France |
| authorships[16].institutions[0].id | https://openalex.org/I4210155195 |
| authorships[16].institutions[0].ror | https://ror.org/05cpv3t46 |
| authorships[16].institutions[0].type | healthcare |
| authorships[16].institutions[0].lineage | https://openalex.org/I3018718406, https://openalex.org/I4210155195 |
| authorships[16].institutions[0].country_code | FR |
| authorships[16].institutions[0].display_name | Hôpital Claude Huriez |
| authorships[16].author_position | middle |
| authorships[16].raw_author_name | David Beauvais |
| authorships[16].is_corresponding | False |
| authorships[16].raw_affiliation_strings | Department of Haematology Hôpital Claude Huriez, Lille University Hospital Lille France |
| authorships[17].author.id | https://openalex.org/A5042516164 |
| authorships[17].author.orcid | https://orcid.org/0000-0002-8615-6254 |
| authorships[17].author.display_name | Brian A. Walker |
| authorships[17].countries | US |
| authorships[17].affiliations[0].institution_ids | https://openalex.org/I79620101 |
| authorships[17].affiliations[0].raw_affiliation_string | Myeloma Centre, University of Arkansas for Medical Sciences, Little Rock, AR, USA |
| authorships[17].institutions[0].id | https://openalex.org/I79620101 |
| authorships[17].institutions[0].ror | https://ror.org/00xcryt71 |
| authorships[17].institutions[0].type | education |
| authorships[17].institutions[0].lineage | https://openalex.org/I79620101 |
| authorships[17].institutions[0].country_code | US |
| authorships[17].institutions[0].display_name | University of Arkansas for Medical Sciences |
| authorships[17].author_position | middle |
| authorships[17].raw_author_name | Brian A. Walker |
| authorships[17].is_corresponding | False |
| authorships[17].raw_affiliation_strings | Myeloma Centre, University of Arkansas for Medical Sciences, Little Rock, AR, USA |
| authorships[18].author.id | https://openalex.org/A5084133067 |
| authorships[18].author.orcid | https://orcid.org/0000-0002-9416-7818 |
| authorships[18].author.display_name | Christopher P. Wardell |
| authorships[18].countries | US |
| authorships[18].affiliations[0].institution_ids | https://openalex.org/I79620101 |
| authorships[18].affiliations[0].raw_affiliation_string | Myeloma Centre, University of Arkansas for Medical Sciences, Little Rock, AR, USA |
| authorships[18].institutions[0].id | https://openalex.org/I79620101 |
| authorships[18].institutions[0].ror | https://ror.org/00xcryt71 |
| authorships[18].institutions[0].type | education |
| authorships[18].institutions[0].lineage | https://openalex.org/I79620101 |
| authorships[18].institutions[0].country_code | US |
| authorships[18].institutions[0].display_name | University of Arkansas for Medical Sciences |
| authorships[18].author_position | middle |
| authorships[18].raw_author_name | Christopher P. Wardell |
| authorships[18].is_corresponding | False |
| authorships[18].raw_affiliation_strings | Myeloma Centre, University of Arkansas for Medical Sciences, Little Rock, AR, USA |
| authorships[19].author.id | https://openalex.org/A5076452184 |
| authorships[19].author.orcid | https://orcid.org/0000-0001-5904-1286 |
| authorships[19].author.display_name | Laure Vincent |
| authorships[19].countries | FR |
| authorships[19].affiliations[0].institution_ids | https://openalex.org/I4210093292 |
| authorships[19].affiliations[0].raw_affiliation_string | Department of Haematology, CHU Montpellier, Montpellier, France |
| authorships[19].institutions[0].id | https://openalex.org/I4210093292 |
| authorships[19].institutions[0].ror | https://ror.org/00mthsf17 |
| authorships[19].institutions[0].type | healthcare |
| authorships[19].institutions[0].lineage | https://openalex.org/I4210093292 |
| authorships[19].institutions[0].country_code | FR |
| authorships[19].institutions[0].display_name | Centre Hospitalier Universitaire de Montpellier |
| authorships[19].author_position | middle |
| authorships[19].raw_author_name | Laure Vincent |
| authorships[19].is_corresponding | False |
| authorships[19].raw_affiliation_strings | Department of Haematology, CHU Montpellier, Montpellier, France |
| authorships[20].author.id | https://openalex.org/A5091463936 |
| authorships[20].author.orcid | https://orcid.org/0000-0002-6085-2163 |
| authorships[20].author.display_name | Laurent Frenzel |
| authorships[20].countries | FR |
| authorships[20].affiliations[0].institution_ids | https://openalex.org/I1288880153, https://openalex.org/I4210097159 |
| authorships[20].affiliations[0].raw_affiliation_string | Department of Clinical Haematology, AP-HP, Necker Hospital, Paris, France |
| authorships[20].institutions[0].id | https://openalex.org/I4210097159 |
| authorships[20].institutions[0].ror | https://ror.org/00pg5jh14 |
| authorships[20].institutions[0].type | healthcare |
| authorships[20].institutions[0].lineage | https://openalex.org/I4210097159 |
| authorships[20].institutions[0].country_code | FR |
| authorships[20].institutions[0].display_name | Assistance Publique – Hôpitaux de Paris |
| authorships[20].institutions[1].id | https://openalex.org/I1288880153 |
| authorships[20].institutions[1].ror | https://ror.org/05tr67282 |
| authorships[20].institutions[1].type | healthcare |
| authorships[20].institutions[1].lineage | https://openalex.org/I1288880153, https://openalex.org/I4210097159, https://openalex.org/I4210120235 |
| authorships[20].institutions[1].country_code | FR |
| authorships[20].institutions[1].display_name | Hôpital Necker-Enfants Malades |
| authorships[20].author_position | middle |
| authorships[20].raw_author_name | Laurent Frenzel |
| authorships[20].is_corresponding | False |
| authorships[20].raw_affiliation_strings | Department of Clinical Haematology, AP-HP, Necker Hospital, Paris, France |
| authorships[21].author.id | https://openalex.org/A5023937847 |
| authorships[21].author.orcid | https://orcid.org/0000-0001-9725-9323 |
| authorships[21].author.display_name | Hélène Caillon |
| authorships[21].countries | FR |
| authorships[21].affiliations[0].institution_ids | https://openalex.org/I97188460 |
| authorships[21].affiliations[0].raw_affiliation_string | Department of Biochemistry, University Hospital of Nantes, Nantes, France |
| authorships[21].institutions[0].id | https://openalex.org/I97188460 |
| authorships[21].institutions[0].ror | https://ror.org/03gnr7b55 |
| authorships[21].institutions[0].type | education |
| authorships[21].institutions[0].lineage | https://openalex.org/I97188460 |
| authorships[21].institutions[0].country_code | FR |
| authorships[21].institutions[0].display_name | Nantes Université |
| authorships[21].author_position | middle |
| authorships[21].raw_author_name | Hélène Caillon |
| authorships[21].is_corresponding | False |
| authorships[21].raw_affiliation_strings | Department of Biochemistry, University Hospital of Nantes, Nantes, France |
| authorships[22].author.id | https://openalex.org/A5061161544 |
| authorships[22].author.orcid | |
| authorships[22].author.display_name | Susanna Schraen |
| authorships[22].countries | FR |
| authorships[22].affiliations[0].institution_ids | https://openalex.org/I2279609970 |
| authorships[22].affiliations[0].raw_affiliation_string | Department of Biochemistry, Biology Pathology Centre, Lille University Hospital, Lille, France |
| authorships[22].institutions[0].id | https://openalex.org/I2279609970 |
| authorships[22].institutions[0].ror | https://ror.org/02kzqn938 |
| authorships[22].institutions[0].type | education |
| authorships[22].institutions[0].lineage | https://openalex.org/I2279609970 |
| authorships[22].institutions[0].country_code | FR |
| authorships[22].institutions[0].display_name | Université de Lille |
| authorships[22].author_position | middle |
| authorships[22].raw_author_name | Schraen Susanna |
| authorships[22].is_corresponding | False |
| authorships[22].raw_affiliation_strings | Department of Biochemistry, Biology Pathology Centre, Lille University Hospital, Lille, France |
| authorships[23].author.id | https://openalex.org/A5021139263 |
| authorships[23].author.orcid | https://orcid.org/0000-0002-5080-6585 |
| authorships[23].author.display_name | Thomas Dejoie |
| authorships[23].countries | FR |
| authorships[23].affiliations[0].institution_ids | https://openalex.org/I97188460 |
| authorships[23].affiliations[0].raw_affiliation_string | Department of Biochemistry, University Hospital of Nantes, Nantes, France |
| authorships[23].institutions[0].id | https://openalex.org/I97188460 |
| authorships[23].institutions[0].ror | https://ror.org/03gnr7b55 |
| authorships[23].institutions[0].type | education |
| authorships[23].institutions[0].lineage | https://openalex.org/I97188460 |
| authorships[23].institutions[0].country_code | FR |
| authorships[23].institutions[0].display_name | Nantes Université |
| authorships[23].author_position | middle |
| authorships[23].raw_author_name | Thomas Dejoie |
| authorships[23].is_corresponding | False |
| authorships[23].raw_affiliation_strings | Department of Biochemistry, University Hospital of Nantes, Nantes, France |
| authorships[24].author.id | https://openalex.org/A5063422967 |
| authorships[24].author.orcid | https://orcid.org/0000-0002-3050-0140 |
| authorships[24].author.display_name | Hervé Avet‐Loiseau |
| authorships[24].countries | FR |
| authorships[24].affiliations[0].institution_ids | https://openalex.org/I17866349 |
| authorships[24].affiliations[0].raw_affiliation_string | Genomics of Myeloma Unit, University Hospital of Toulouse, Toulouse, France |
| authorships[24].institutions[0].id | https://openalex.org/I17866349 |
| authorships[24].institutions[0].ror | https://ror.org/004raaa70 |
| authorships[24].institutions[0].type | education |
| authorships[24].institutions[0].lineage | https://openalex.org/I17866349 |
| authorships[24].institutions[0].country_code | FR |
| authorships[24].institutions[0].display_name | Université Fédérale de Toulouse Midi-Pyrénées |
| authorships[24].author_position | middle |
| authorships[24].raw_author_name | Hervé Avet‐Loiseau |
| authorships[24].is_corresponding | False |
| authorships[24].raw_affiliation_strings | Genomics of Myeloma Unit, University Hospital of Toulouse, Toulouse, France |
| authorships[25].author.id | https://openalex.org/A5020996390 |
| authorships[25].author.orcid | |
| authorships[25].author.display_name | Mohamad Mohty |
| authorships[25].countries | FR |
| authorships[25].affiliations[0].institution_ids | https://openalex.org/I39804081, https://openalex.org/I4210097159, https://openalex.org/I4210102928 |
| authorships[25].affiliations[0].raw_affiliation_string | Department of Haematology Hôpital Saint Antoine, APHP Paris France |
| authorships[25].institutions[0].id | https://openalex.org/I4210097159 |
| authorships[25].institutions[0].ror | https://ror.org/00pg5jh14 |
| authorships[25].institutions[0].type | healthcare |
| authorships[25].institutions[0].lineage | https://openalex.org/I4210097159 |
| authorships[25].institutions[0].country_code | FR |
| authorships[25].institutions[0].display_name | Assistance Publique – Hôpitaux de Paris |
| authorships[25].institutions[1].id | https://openalex.org/I4210102928 |
| authorships[25].institutions[1].ror | https://ror.org/01875pg84 |
| authorships[25].institutions[1].type | healthcare |
| authorships[25].institutions[1].lineage | https://openalex.org/I4210097159, https://openalex.org/I4210102928 |
| authorships[25].institutions[1].country_code | FR |
| authorships[25].institutions[1].display_name | Hôpital Saint-Antoine |
| authorships[25].institutions[2].id | https://openalex.org/I39804081 |
| authorships[25].institutions[2].ror | https://ror.org/02en5vm52 |
| authorships[25].institutions[2].type | education |
| authorships[25].institutions[2].lineage | https://openalex.org/I39804081 |
| authorships[25].institutions[2].country_code | FR |
| authorships[25].institutions[2].display_name | Sorbonne Université |
| authorships[25].author_position | middle |
| authorships[25].raw_author_name | Mohamad Mohty |
| authorships[25].is_corresponding | False |
| authorships[25].raw_affiliation_strings | Department of Haematology Hôpital Saint Antoine, APHP Paris France |
| authorships[26].author.id | https://openalex.org/A5024315315 |
| authorships[26].author.orcid | https://orcid.org/0000-0001-7705-8460 |
| authorships[26].author.display_name | Thierry Façon |
| authorships[26].countries | FR |
| authorships[26].affiliations[0].institution_ids | https://openalex.org/I4210155195 |
| authorships[26].affiliations[0].raw_affiliation_string | Department of Haematology Hôpital Claude Huriez, Lille University Hospital Lille France |
| authorships[26].institutions[0].id | https://openalex.org/I4210155195 |
| authorships[26].institutions[0].ror | https://ror.org/05cpv3t46 |
| authorships[26].institutions[0].type | healthcare |
| authorships[26].institutions[0].lineage | https://openalex.org/I3018718406, https://openalex.org/I4210155195 |
| authorships[26].institutions[0].country_code | FR |
| authorships[26].institutions[0].display_name | Hôpital Claude Huriez |
| authorships[26].author_position | last |
| authorships[26].raw_author_name | Thierry Facon |
| authorships[26].is_corresponding | True |
| authorships[26].raw_affiliation_strings | Department of Haematology Hôpital Claude Huriez, Lille University Hospital Lille France |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bjh.16059 |
| open_access.oa_status | bronze |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014‐04 (Etoile du Nord) trial |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10649 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 1.0 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2720 |
| primary_topic.subfield.display_name | Hematology |
| primary_topic.display_name | Multiple Myeloma Research and Treatments |
| related_works | https://openalex.org/W2607449242, https://openalex.org/W4205134795, https://openalex.org/W4229583511, https://openalex.org/W2980731506, https://openalex.org/W2507453208, https://openalex.org/W4232181847, https://openalex.org/W2472135629, https://openalex.org/W2981135983, https://openalex.org/W2192430028, https://openalex.org/W2563047534 |
| cited_by_count | 22 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 1 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 2 |
| counts_by_year[2].year | 2023 |
| counts_by_year[2].cited_by_count | 5 |
| counts_by_year[3].year | 2022 |
| counts_by_year[3].cited_by_count | 3 |
| counts_by_year[4].year | 2021 |
| counts_by_year[4].cited_by_count | 5 |
| counts_by_year[5].year | 2020 |
| counts_by_year[5].cited_by_count | 3 |
| counts_by_year[6].year | 2019 |
| counts_by_year[6].cited_by_count | 3 |
| locations_count | 5 |
| best_oa_location.id | doi:10.1111/bjh.16059 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S153015021 |
| best_oa_location.source.issn | 0007-1048, 1365-2141 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 0007-1048 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | British Journal of Haematology |
| best_oa_location.source.host_organization | https://openalex.org/P4310320595 |
| best_oa_location.source.host_organization_name | Wiley |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320595 |
| best_oa_location.license | |
| best_oa_location.pdf_url | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bjh.16059 |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | British Journal of Haematology |
| best_oa_location.landing_page_url | https://doi.org/10.1111/bjh.16059 |
| primary_location.id | doi:10.1111/bjh.16059 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S153015021 |
| primary_location.source.issn | 0007-1048, 1365-2141 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 0007-1048 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | British Journal of Haematology |
| primary_location.source.host_organization | https://openalex.org/P4310320595 |
| primary_location.source.host_organization_name | Wiley |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320595 |
| primary_location.license | |
| primary_location.pdf_url | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bjh.16059 |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | British Journal of Haematology |
| primary_location.landing_page_url | https://doi.org/10.1111/bjh.16059 |
| publication_date | 2019-06-19 |
| publication_year | 2019 |
| referenced_works | https://openalex.org/W2167571044, https://openalex.org/W1978377409, https://openalex.org/W2688500010, https://openalex.org/W2767761069, https://openalex.org/W2905925521, https://openalex.org/W2252820304, https://openalex.org/W4249503099, https://openalex.org/W2044436186, https://openalex.org/W2400276917, https://openalex.org/W2140579395, https://openalex.org/W1902692042, https://openalex.org/W2229483068, https://openalex.org/W2909546334, https://openalex.org/W2041469831, https://openalex.org/W2331857836, https://openalex.org/W2153836018, https://openalex.org/W4211037848, https://openalex.org/W2090247445, https://openalex.org/W2807762966, https://openalex.org/W2966673846, https://openalex.org/W2402003835, https://openalex.org/W2610536291, https://openalex.org/W2141502099, https://openalex.org/W1977523785 |
| referenced_works_count | 24 |
| abstract_inverted_index.( | 72, 78 |
| abstract_inverted_index.4 | 100 |
| abstract_inverted_index.= | 74, 80 |
| abstract_inverted_index.a | 87, 120, 189 |
| abstract_inverted_index.n | 73, 79 |
| abstract_inverted_index.OS | 142 |
| abstract_inverted_index.an | 194 |
| abstract_inverted_index.du | 17 |
| abstract_inverted_index.in | 8, 27, 31, 39, 54, 188 |
| abstract_inverted_index.of | 148, 158 |
| abstract_inverted_index.or | 47, 92, 122, 174 |
| abstract_inverted_index.to | 23, 97, 113, 171 |
| abstract_inverted_index.19) | 75 |
| abstract_inverted_index.33% | 71 |
| abstract_inverted_index.48% | 77 |
| abstract_inverted_index.For | 102, 137 |
| abstract_inverted_index.The | 14, 61, 94, 125, 156 |
| abstract_inverted_index.all | 131, 163 |
| abstract_inverted_index.and | 57, 65, 76, 167, 185 |
| abstract_inverted_index.did | 168 |
| abstract_inverted_index.for | 59, 117, 130, 198 |
| abstract_inverted_index.has | 4 |
| abstract_inverted_index.not | 169 |
| abstract_inverted_index.the | 55, 66, 105, 140 |
| abstract_inverted_index.was | 21, 99, 109, 133, 143, 153, 161 |
| abstract_inverted_index.(OS) | 129 |
| abstract_inverted_index.27), | 81 |
| abstract_inverted_index.37%; | 162 |
| abstract_inverted_index.3·7 | 114 |
| abstract_inverted_index.6·6 | 110 |
| abstract_inverted_index.Five | 83 |
| abstract_inverted_index.RRMM | 33 |
| abstract_inverted_index.data | 179 |
| abstract_inverted_index.dose | 172 |
| abstract_inverted_index.good | 89 |
| abstract_inverted_index.lead | 170 |
| abstract_inverted_index.rate | 64, 69 |
| abstract_inverted_index.that | 147, 181 |
| abstract_inverted_index.time | 96 |
| abstract_inverted_index.very | 88 |
| abstract_inverted_index.were | 52, 70, 165 |
| abstract_inverted_index.with | 29, 41, 119, 150, 183, 193, 200 |
| abstract_inverted_index.16·7 | 134 |
| abstract_inverted_index.2·97 | 154 |
| abstract_inverted_index.RRMM. | 202 |
| abstract_inverted_index.These | 178 |
| abstract_inverted_index.agent | 2 |
| abstract_inverted_index.cases | 164 |
| abstract_inverted_index.shown | 5 |
| abstract_inverted_index.those | 118 |
| abstract_inverted_index.trial | 20, 56 |
| abstract_inverted_index.until | 44 |
| abstract_inverted_index.23·23 | 144 |
| abstract_inverted_index.Single | 1 |
| abstract_inverted_index.median | 95, 106, 126, 141 |
| abstract_inverted_index.months | 115, 135 |
| abstract_inverted_index.safety | 196 |
| abstract_inverted_index.stable | 123 |
| abstract_inverted_index.triple | 32, 201 |
| abstract_inverted_index.weekly | 42 |
| abstract_inverted_index.weeks. | 101 |
| abstract_inverted_index.(8·8%) | 84 |
| abstract_inverted_index.(RRMM). | 13 |
| abstract_inverted_index.Summary | 0 |
| abstract_inverted_index.benefit | 68, 192 |
| abstract_inverted_index.better. | 93 |
| abstract_inverted_index.disease | 45, 152 |
| abstract_inverted_index.further | 24 |
| abstract_inverted_index.minimal | 121 |
| abstract_inverted_index.months, | 111, 145 |
| abstract_inverted_index.months. | 155 |
| abstract_inverted_index.myeloma | 12 |
| abstract_inverted_index.overall | 62, 127 |
| abstract_inverted_index.partial | 90 |
| abstract_inverted_index.profile | 197 |
| abstract_inverted_index.results | 187 |
| abstract_inverted_index.whereas | 146 |
| abstract_inverted_index.Myélome | 18 |
| abstract_inverted_index.Patients | 35 |
| abstract_inverted_index.achieved | 86 |
| abstract_inverted_index.activity | 7 |
| abstract_inverted_index.clinical | 6, 67 |
| abstract_inverted_index.compared | 112 |
| abstract_inverted_index.designed | 22 |
| abstract_inverted_index.disease. | 124 |
| abstract_inverted_index.included | 53 |
| abstract_inverted_index.multiple | 11 |
| abstract_inverted_index.patients | 51, 85, 132, 149, 199 |
| abstract_inverted_index.received | 36 |
| abstract_inverted_index.response | 63, 91, 98 |
| abstract_inverted_index.survival | 108, 128 |
| abstract_inverted_index.2014‐04 | 19 |
| abstract_inverted_index.evaluable | 58 |
| abstract_inverted_index.incidence | 157 |
| abstract_inverted_index.infusions | 38 |
| abstract_inverted_index.patients, | 104, 139 |
| abstract_inverted_index.patients. | 34 |
| abstract_inverted_index.permanent | 175 |
| abstract_inverted_index.reactions | 160 |
| abstract_inverted_index.reduction | 173 |
| abstract_inverted_index.relapsed, | 9 |
| abstract_inverted_index.response. | 60 |
| abstract_inverted_index.toxicity. | 49 |
| abstract_inverted_index.treatment | 176, 182 |
| abstract_inverted_index.acceptable | 195 |
| abstract_inverted_index.manageable | 166 |
| abstract_inverted_index.meaningful | 190 |
| abstract_inverted_index.refractory | 10 |
| abstract_inverted_index.responding | 103, 138 |
| abstract_inverted_index.Francophone | 16 |
| abstract_inverted_index.Intergroupe | 15 |
| abstract_inverted_index.combination | 28, 40 |
| abstract_inverted_index.daratumumab | 3, 26, 37, 184 |
| abstract_inverted_index.demonstrate | 180 |
| abstract_inverted_index.investigate | 25 |
| abstract_inverted_index.long‐term | 191 |
| abstract_inverted_index.progression | 46 |
| abstract_inverted_index.progressive | 151 |
| abstract_inverted_index.unacceptable | 48 |
| abstract_inverted_index.(3·0–5·5) | 116 |
| abstract_inverted_index.Fifty‐seven | 50 |
| abstract_inverted_index.dexamethasone | 30, 43, 186 |
| abstract_inverted_index.respectively. | 82 |
| abstract_inverted_index.(11·2–24·0). | 136 |
| abstract_inverted_index.discontinuation. | 177 |
| abstract_inverted_index.infusion‐related | 159 |
| abstract_inverted_index.progression‐free | 107 |
| cited_by_percentile_year.max | 98 |
| cited_by_percentile_year.min | 91 |
| corresponding_author_ids | https://openalex.org/A5024315315 |
| countries_distinct_count | 3 |
| institutions_distinct_count | 27 |
| corresponding_institution_ids | https://openalex.org/I4210155195 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8399999737739563 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.88897196 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | True |